Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18068142 | 0.81 | BCHE (0.36) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL2013279 | 0.81 | NOS1 (0.46) | BCHEBUB1HSP90AA1HSP90AB1GPR119 | |
| SCHEMBL2959354 | 0.81 | BCHE (0.38) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL159357 | 0.81 | BCHE (0.38) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL22952412 | 0.79 | BCHE (0.37) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL17377610 | 0.79 | BCHE (0.37) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL306662 | 0.79 | HSP90AA1 (0.39) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL2006922 | 0.79 | BCHE (0.35) | BCHEROCK2BUB1HSP90AA1HSP90AB1 | |
| SCHEMBL22290799 | 0.78 | CYP4F2 (0.39) | BCHEPOLBELANEMEN1KMT2A | |
| SCHEMBL17633162 | 0.78 | CYP4F2 (0.39) | BCHEROCK2BUB1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036731-A | CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof | 北京康辰药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-3971187-B1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116444515-A | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3971187-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| CN-112368283-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| WO-2020228756-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228756-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| EP-3538525-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | BCHE 3899/4885ROCK2 747/4885BUB1 3772/4885 |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | BCHE 4554/4885ROCK2 1203/4885BUB1 3904/4885 |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | BCHE 411/4885ROCK2 1624/4885BUB1 4362/4885 |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | RET, REL, GOT1 | BCHE 1018/4885ROCK2 842/4885BUB1 4300/4885 |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | BCHE 4391/4885ROCK2 1180/4885BUB1 3766/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | BCHE 4172/4885ROCK2 805/4885BUB1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.